Inclusion Criteria:

          1. Histologically confirmed diagnosis of CD123+ AML per the US National Comprehensive
             Cancer Network (NCCN) Clinical Practice Guidelines for Acute Myeloid Leukemia
             (2016.v1);

          2. Relapsed or refractory CD123+ AML (meeting one of the following conditions):

               1. CR not achieved after standardized chemotherapy;

               2. CR achieved following the first induction, but CR duration is less than 12
                  months;

               3. Ineffectively after first or multiple remedial treatments;

               4. 2 or more relapses;

          3. The number of primordial cells in bone marrow is > 5% (by morphology), and/or > 0.01%
             (by flowcytometry);

          4. Total bilirubin ≤ 51 umol/L, ALT and AST ≤ 3 times of upper limit ofnormal, creatinine
             ≤ 176.8 umol/L;

          5. Echocardiogram shows left ventricular ejection fraction (LVEF) ≥50%;

          6. No active infection in the lungs, blood oxygen saturation in indoorair is ≥ 92%;

          7. Estimated survival time ≥ 3 months;

          8. ECOG performance status 0 to 2;

          9. Patients or their legal guardians volunteer to participate in the studyand sign the
             informed consent.

        Exclusion Criteria:

        Subjects with any of the following exclusion criteria were not eligible for this trial:

          1. History of craniocerebral trauma, conscious disturbance,epilepsy,cerebrovascular
             ischemia, and cerebrovascular, hemorrhagicdiseases;

          2. Electrocardiogram shows prolonged QT interval, severe heart diseasessuch as severe
             arrhythmia in the past;

          3. Pregnant (or lactating) women;

          4. Patients with severe active infections (excluding simple urinarytractinfectionand
             bacterial pharyngitis);

          5. Active infection of hepatitis B virus or hepatitis C virus;

          6. Concurrent therapy with systemic steroids within 2 weeks prior toscreening, except for
             the patients recently or currently receiving in haledsteroids;

          7. Previously treated with any CAR-T cell product or other genetically-modified T cell
             therapies;

          8. Creatinine>2.5mg/dl, or ALT / AST > 3 times of normal amounts, or bilirubin>2.0 mg/dl;

          9. Other uncontrolled diseases that were not suitable for this trial;

         10. Patients with HIV infection;

         11. Any situations that the investigator believes may increase the risk ofpatients or
             interfere with the results of study.